AIGEN Sciences

AIGEN Sciences provides AI-based drug discovery and design tools for researchers, featuring its proprietary AIGEN Discovery platform. The system assists with the discovery and design of new drugs using artificial intelligence and machine learning to accelerate the pharmaceutical research process. The platform can be used for target identification, lead compound optimization, molecular property prediction, and other computational chemistry applications. AIGEN Sciences serves pharmaceutical companies, biotech firms, and academic research institutions, helping them reduce the time and cost associated with traditional drug discovery workflows. Founded in 2021 and headquartered in Seoul, South Korea, AIGEN Sciences has raised approximately $8.8 million in Series A funding from investors including Premier Partners, K2 Investment Partners, Medytox Venture, Partners Investment, QUAD, Scale Up Partners, and Hyosung Ventures.